Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, UK.
Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, UK.
Pharmacol Res Perspect. 2021 May;9(3):e00779. doi: 10.1002/prp2.779.
Fluorescent ligand technologies have proved to be powerful tools to improve our understanding of ligand-receptor interactions. Here we have characterized a small focused library of nine fluorescent ligands based on the highly selective β -adrenoceptor (β AR) antagonist ICI 118,551. The majority of fluorescent ICI 118,551 analogs had good affinity for the β AR (pK >7.0) with good selectivity over the β AR (pK <6.0). The most potent and selective ligands being 8c (ICI 118,551-Gly-Ala-BODIPY-FL-X; β AR pK 7.48), 9c (ICI 118,551-βAla-βAla-BODIPY-FL-X; β AR pK 7.48), 12a (ICI 118,551-PEG-BODIPY-X-630/650; β AR pK 7.56), and 12b (ICI 118,551-PEG-BODIPY-FL; β AR pK 7.42). 9a (ICI 118,551-βAla-βAla-BODIPY-X-630/650) had the highest affinity at recombinant β ARs (pK 7.57), but also exhibited significant binding affinity to the β AR (pK 6.69). Nevertheless, among the red fluorescent ligands, 9a had the best imaging characteristics in recombinant HEK293 T cells and labeling was mostly confined to the cell surface. In contrast, 12a showed the highest propensity to label intracellular β ARs in HEK293 T cell expressing exogenous β ARs. This suggests that a combination of the polyethylene glycol (PEG) linker and the BODIPY-X-630/650 makes this ICI 118,551 derivative particularly susceptible to crossing the cell membrane to access the intracellular β ARs. We have also used these ligands in combination with CRISPR/Cas9 genome-edited HEK293 T cells to undertake for the first time real-time ligand binding to native HEK293 T β ARs at low native receptor expression levels. These studies provided quantitative data on ligand-binding characteristics but also allowed real-time visualization of the ligand-binding interactions in genome-edited cells using NanoBRET luminescence imaging.
荧光配体技术已被证明是一种强大的工具,可以帮助我们深入了解配体-受体相互作用。在这里,我们基于高选择性β-肾上腺素能受体(βAR)拮抗剂 ICI 118,551 对一个小型的聚焦文库进行了研究。大多数荧光 ICI 118,551 类似物对βAR(pK >7.0)具有良好的亲和力,并且对βAR(pK <6.0)具有良好的选择性。最有效和选择性的配体为 8c(ICI 118,551-Gly-Ala-BODIPY-FL-X;βAR pK 7.48)、9c(ICI 118,551-βAla-βAla-BODIPY-FL-X;βAR pK 7.48)、12a(ICI 118,551-PEG-BODIPY-X-630/650;βAR pK 7.56)和 12b(ICI 118,551-PEG-BODIPY-FL;βAR pK 7.42)。9a(ICI 118,551-βAla-βAla-BODIPY-X-630/650)在重组βAR 上具有最高的亲和力(pK 7.57),但也表现出对βAR(pK 6.69)的显著结合亲和力。然而,在红色荧光配体中,9a 在重组 HEK293 T 细胞中的成像特性最佳,并且标记主要局限于细胞膜。相比之下,12a 在表达外源性βAR 的 HEK293 T 细胞中显示出对细胞内βAR 进行标记的最高倾向。这表明聚乙二醇(PEG)接头和 BODIPY-X-630/650 的组合使这种 ICI 118,551 衍生物特别容易穿过细胞膜来接触细胞内的βAR。我们还将这些配体与 CRISPR/Cas9 基因组编辑的 HEK293 T 细胞一起使用,首次在低天然受体表达水平下对天然 HEK293 TβAR 进行实时配体结合研究。这些研究提供了关于配体结合特征的定量数据,并且还允许使用 NanoBRET 发光成像实时可视化基因组编辑细胞中的配体结合相互作用。